Loading
A phase 2 trial of 120 mg LY2784544 in myeloproliferative neoplasms, run by Eli Lilly and Company, active and no longer recruiting.
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms is a phase 2 interventional study registered as NCT01594723 by Eli Lilly and Company, with 110 participants enrolled, started 2012-05-22 and due to reach its primary completion in 2015-03-20. Interventions recorded: 120 mg LY2784544.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/